{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:25:21Z","timestamp":1778657121777,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse intrinsic pontine glioma (DIPG).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Biweekly bevacizumab (10 mg\/kg) and irinotecan (125 mg\/m<jats:sup>2<\/jats:sup>) were combined with daily erlotinib. Two cohorts received increasing doses of erlotinib (65 and 85 mg\/m<jats:sup>2<\/jats:sup>) following a 3 + 3 dose-escalation schedule, until disease progression with a maximum of one year. Dose-limiting toxicities (DLT) were monitored biweekly. Secondary progression free survival (sPFS) and overall survival (OS) were determined based on clinical and radiological response measurements. Quality of life (QoL) during treatment was also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between November 2011 and March 2018, nine patients with disease progression after initial radiotherapy were enrolled. Median PFS at start of the study was 7.3 months (range 3.5\u201310.0). In the first dose cohort, one patient experienced a DLT (grade III acute diarrhea), resulting in enrollment of three additional patients in this cohort. No additional DLTs were observed in consecutive patients receiving up to a maximum dose of 85 mg\/m<jats:sup>2<\/jats:sup>. Median sPFS was 3.2 months (range 1.0\u201310.9), and median OS was 13.8 months (range 9.3\u201333.0). Overall QoL was stable during treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Daily erlotinib is safe and well tolerated in doses up to 85 mg\/m<jats:sup>2<\/jats:sup> when combined with biweekly bevacizumab and irinotecan in children with progressive DIPG. Median OS of the study patients was longer than known form literature.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-021-03763-1","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T17:04:12Z","timestamp":1620407052000},"page":"263-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A phase I\/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma"],"prefix":"10.1007","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-8516","authenticated-orcid":false,"given":"Fatma E.","family":"El-Khouly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie E. M.","family":"Veldhuijzen van Zanten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewi P.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Sanchez Aliaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Peter","family":"Vandertop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dannis G.","family":"van Vuurden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertjan J. L.","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"19","key":"3763_CR1","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO10.1200\/JCO.2017","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary SN, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih C, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren A, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M (2018) Clinical, Radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 36(19):1963\u20131972. https:\/\/doi.org\/10.1200\/JCO10.1200\/JCO.2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"3763_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nou104","volume":"17","author":"MH Jansen","year":"2015","unstructured":"Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS, Reddingius R, Peeters CM, Schouten-van Meeteren AY, Gooskens RH, Granzen B, Paardekooper GM, Janssens GO, Noske DP, Barkhof F, Kramm CM, Vandertop WP, Kaspers GJ, van Vuurden DG (2015) Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 17(1):160\u2013166. https:\/\/doi.org\/10.1093\/neuonc\/nou104","journal-title":"Neuro Oncol"},{"issue":"8","key":"3763_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza NA, Monje M (2019) Diffuse Intrinsic Pontine Glioma: From Diagnosis To Next-Generation Clinical Trials. Curr Treat Options Neurol 21(8):37. https:\/\/doi.org\/10.1007\/s11940-019-0577-y","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"3763_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00263825","volume":"7","author":"IA Langmoen","year":"1991","unstructured":"Langmoen IA, Lundar T, Storm-Mathisen I, Lie SO, Hovind KH (1991) Management of pediatric pontine gliomas. Childs Nerv Syst 7(1):13\u201315","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"3763_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/14737140.2015.974563","volume":"15","author":"SE Veldhuijzen van Zanten","year":"2015","unstructured":"Veldhuijzen van Zanten SE, Jansen MH, Sanchez Aliaga E, van Vuurden DG, Vandertop WP, Kaspers GJ (2015) A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther 15(2):157\u2013164. https:\/\/doi.org\/10.1586\/14737140.2015.974563","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"3763_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"7326","key":"3763_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973\u2013977. https:\/\/doi.org\/10.1038\/nature09626","journal-title":"Nature"},{"issue":"7326","key":"3763_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968\u2013972. https:\/\/doi.org\/10.1038\/nature09627","journal-title":"Nature"},{"issue":"4","key":"3763_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253\u20131259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2309","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3763_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/02841860802537924","volume":"48","author":"HS Poulsen","year":"2009","unstructured":"Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U (2009) Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48(1):52\u201358. https:\/\/doi.org\/10.1080\/02841860802537924","journal-title":"Acta Oncol"},{"issue":"7","key":"3763_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/pbc.21935","volume":"52","author":"RJ Packer","year":"2009","unstructured":"Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52(7):791\u2013795. https:\/\/doi.org\/10.1002\/pbc.21935","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"3763_CR12","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","volume":"28","author":"S Gururangan","year":"2010","unstructured":"Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28(18):3069\u20133075. https:\/\/doi.org\/10.1200\/JCO.2009.26.8789","journal-title":"J Clin Oncol"},{"issue":"7","key":"3763_CR13","first-page":"1786","volume":"5","author":"M Bredel","year":"1999","unstructured":"Bredel M, Pollack IF, Hamilton RL, James CD (1999) Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5(7):1786\u20131792","journal-title":"Clin Cancer Res"},{"issue":"10 Pt 1","key":"3763_CR14","first-page":"3620","volume":"9","author":"RJ Gilbertson","year":"2003","unstructured":"Gilbertson RJ, Hill DA, Hernan R, Kocak M, Geyer R, Olson J, Gajjar A, Rush L, Hamilton RL, Finkelstein SD, Pollack IF (2003) ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 9(10 Pt 1):3620\u20133624","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3763_CR15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","volume":"28","author":"M Zarghooni","year":"2010","unstructured":"Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28(8):1337\u20131344. https:\/\/doi.org\/10.1200\/JCO.2009.25.5463","journal-title":"J Clin Oncol"},{"issue":"2","key":"3763_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172\u2013187. https:\/\/doi.org\/10.1056\/NEJMra044389","journal-title":"N Engl J Med"},{"issue":"30","key":"3763_CR17","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1200\/JCO.2007.15.2306","volume":"26","author":"RI Jakacki","year":"2008","unstructured":"Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children\u2019s Oncology Group Phase I Consortium Study. J Clin Oncol 26(30):4921\u20134927. https:\/\/doi.org\/10.1200\/JCO.2007.15.2306","journal-title":"J Clin Oncol"},{"issue":"2","key":"3763_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1078-0432.CCR-08-1923","volume":"15","author":"A Broniscer","year":"2009","unstructured":"Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, Kocak M, Morris EB, Endersby R, Ellison DW, Gajjar A (2009) Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 15(2):701\u2013707. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1923","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3763_CR19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","volume":"28","author":"T Shih","year":"2006","unstructured":"Shih T, KLindley C, (2006) Bevacizumab: an agiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779\u20131802. https:\/\/doi.org\/10.1016\/j.clinthera.2006.11.015","journal-title":"Clin Ther"},{"issue":"2","key":"3763_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-017-2575-9","volume":"135","author":"SEM Veldhuijzen van Zanten","year":"2017","unstructured":"Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, Wolf NI, Zwaan CM, Vandertop WP, van Vuurden DG, Kaspers GJL (2017) A phase I\/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 135(2):307\u2013315. https:\/\/doi.org\/10.1007\/s11060-017-2575-9","journal-title":"J Neurooncol"},{"issue":"9","key":"3763_CR21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3174\/ajnr.A4782","volume":"37","author":"T Jaspan","year":"2016","unstructured":"Jaspan T, Morgan PS, Warmuth-Metz M, Sanchez Aliaga E, Warren D, Calmon R, Grill J, Hargrave D, Garcia J, Zahlmann G (2016) Response assessment in pediatric neuro-oncology: implementation and expansion of the RANO criteria in a randomized phase ii trial of pediatric patients with newly diagnosed high-grade gliomas. AJNR Am J Neuroradiol 37(9):1581\u20131587. https:\/\/doi.org\/10.3174\/ajnr.A4782","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"3763_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101(10):708\u2013720. https:\/\/doi.org\/10.1093\/jnci\/djp079","journal-title":"J Natl Cancer Inst"},{"key":"3763_CR23","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (2010). National Institutes of Health"},{"key":"3763_CR24","unstructured":"Varni JW (1998\u20132020) The PedsQL\u2122 measurement model for the Pediatric Quality of Life InventoryTM. http:\/\/www.pedsql.org\/about_pedsql.html. Accessed Dec 8 2020"},{"key":"3763_CR25","unstructured":"Varni JW (2017) Scaling and scoring of the Pediatric Quality of Life Inventory\u2122 (PedsQL). http:\/\/www.pedsql.org\/PedsQL-Scoring.pdf. Accessed Dec 8 2020"},{"issue":"3","key":"3763_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11060-016-2141-x","volume":"128","author":"SE Veldhuijzen van Zanten","year":"2016","unstructured":"Veldhuijzen van Zanten SE, Cruz O, Kaspers GJ, Hargrave DR, van Vuurden DG, Network SD (2016) State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. J Neurooncol 128(3):387\u2013394. https:\/\/doi.org\/10.1007\/s11060-016-2141-x","journal-title":"J Neurooncol"},{"issue":"1","key":"3763_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-017-2514-9","volume":"134","author":"SEM Veldhuijzen van Zanten","year":"2017","unstructured":"Veldhuijzen van Zanten SEM, Lane A, Heymans MW, Baugh J, Chaney B, Hoffman LM, Doughman R, Jansen MHA, Sanchez E, Vandertop WP, Kaspers GJL, van Vuurden DG, Fouladi M, Jones BV, Leach J (2017) External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol 134(1):231\u2013240. https:\/\/doi.org\/10.1007\/s11060-017-2514-9","journal-title":"J Neurooncol"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.12.007","volume":"73","author":"GO Janssens","year":"2017","unstructured":"Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG\/DIPG working group. Eur J Cancer 73:38\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.007","journal-title":"Eur J Cancer"},{"issue":"1","key":"3763_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijrobp.2018.12.043","volume":"104","author":"MJ Amsbaugh","year":"2019","unstructured":"Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, Khatua S, Ketonen L, Fontanilla H, McGovern SL (2019) A phase 1\/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 104(1):144\u2013148. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"3763_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO10.1200\/JCO.2017","volume":"36","author":"J Grill","year":"2018","unstructured":"Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Ca\u00f1ete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G (2018) Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 36(10):951\u2013958. https:\/\/doi.org\/10.1200\/JCO10.1200\/JCO.2017","journal-title":"J Clin Oncol"},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/neuonc\/noaa222.083","volume":"22","author":"J Grill","year":"2020","unstructured":"Grill J, Le Teuff G, Nysom K, Blomgren K, Hargrave D, MacCowage G, Bautista F, Van Vuurden DG, Dangouloff-Ross V, Puget S, Varlet P, Debily MA, Vassal G, Le Deley MC (2020) DIPG-35. Biological medicine for diffuse intrinsic pontine glioma (DIPG) eradication: results of the three arm biomarker-driven randomized BIOMEDE 1.0 trial. Neuro Oncology 22:293\u2013294. https:\/\/doi.org\/10.1093\/neuonc\/noaa222.083","journal-title":"Neuro Oncology"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03763-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T18:11:21Z","timestamp":1623953481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03763-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03763-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is part of a larger two-phased clinical trial \u201cA comprehensive and targeted therapy approach in pediatric malignant pontine gliomas\u201d (EudraCT 2009-016080-11, Dutch Trial Register NTR2391), that is approved by the ethical committee of the Amsterdam UMC, location VUmc (METc VUmc, study number: VUMC2010\/164). This study was performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the parents and informed assent was obtained from children aged 12 years and older. Participants have consented to publishing the results of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}}]}}